Photo: Hemant Mishra/MintHyderabad: Biopharmaceutical firm Biocon Ltd on Friday said its partner FUJIFILM Pharma Co. Ltd has launched insulin glargine in Japan. Biopharmaceutical firm Biocon on Friday said its partner FUJIFILM Pharma has launched insulin glargine in JapanBiocon said it will be providing high-quality, yet affordable insulin glargine for Japanese diabetic patients. Insulin glargine, which comes as an injection, has been developed and manufactured by Biocon, and is being commercialized by FUJIFILM in Japan. Biocon markets human insulin or rh-insulin and insulin glargine in India and several emerging markets. The Japanese health regulator approved Biocon’s biosimilar version of long-acting insulin glargine in March.

Source: Mint July 15, 2016 10:03 UTC